Cipla to Acquire 100% stake in Inzpera Healthsciences for INR 111 Crores
Filing Summary
Cipla Ltd. will acquire a 100% stake in Inzpera Healthsciences Limited for a purchase consideration of approximately INR 111 crores in cash. The enterprise value is stated as INR 120 crores. Upon completion, Inzpera will become a wholly-owned subsidiary of Cipla. Inzpera operates in the paediatric pharmaceutical and wellness products sector. The transaction is scheduled for completion within one month. For the fiscal year 2024-25, Inzpera reported a turnover of approximately INR 27 crores. The acquisition is not a related-party transaction.
Cipla Limited has entered into definitive agreements for the acquisition of a 100% stake in Inzpera Healthsciences Limited. The transaction will result in Inzpera becoming a wholly-owned subsidiary of Cipla. The acquisition includes all equity shares and non-convertible redeemable preference shares of Inzpera.
The enterprise value of Inzpera is recorded at INR 120 crores. The total purchase consideration for the acquisition is approximately INR 111 crores, following necessary working capital adjustments. This amount is for the acquisition of 100% of Inzpera’s shareholding. The consideration will be paid entirely in cash. The filing states that the final consideration remains subject to adjustments on the closing date. The transaction is not classified as a related-party transaction.
Inzpera Healthsciences Limited operates within the pharmaceutical industry. The company’s business involves the development, manufacturing, and marketing of differentiated paediatric pharmaceutical and wellness products. The stated object of the acquisition is to combine Inzpera’s product portfolio with Cipla’s distribution network and operational capabilities. All of Inzpera’s current operations are based in India.
Inzpera Healthsciences Limited was incorporated in India on June 22, 2016. The company’s reported turnover for the fiscal year 2024-25 was approximately INR 27 crores. For the fiscal year 2023-24, its turnover was approximately INR 22 crores. The turnover for the fiscal year 2022-23 was approximately INR 21 crores.
The acquisition is scheduled to be completed within one month from the date of the signing of the transaction documents. The timeline for completion can be modified based on mutual agreement between the involved parties. According to the regulatory filing, no specific governmental or regulatory approvals are required for this transaction to proceed.
Cipla Limited is a global pharmaceutical company with a business focus on multiple therapeutic areas, including respiratory, anti-retroviral, urology, and cardiology. The company’s strategic priorities include portfolio expansion in key international markets and development of its product pipeline. Cipla also maintains a presence in the consumer healthcare sector.